PL EN


Preferences help
enabled [disable] Abstract
Number of results
2012 | 12 | 4 | 255-264
Article title

Porównanie działania klozapiny i haloperidolu na grupy tiolowe osocza osób zdrowych

Content
Title variants
EN
The comparison of clozapine and haloperidol effects on plasma thiol groups in healthy subjects
Languages of publication
EN
Abstracts
EN
Differentiated effects of antipsychotics: haloperidol and clozapine on oxidative stress biomarkers were analysed. It has not been determined yet in what way clozapine and haloperidol affect human plasma thiol groups (-SH). The study was aimed at establishing of the effects of haloperidol and clozapine, in doses recommended for treatment of acute episode of schizophrenia, on free thiols in human plasma under in vitro conditions. Material and methods: Blood for the study was collected from 10 healthy male volunteers (aged 24-26 years) for ACD solution. Active substance of the drugs was dissolved in 0.01% dimethyl sulfoxide to the final concentrations (haloperidol 4 ng/ml and 20 ng/ml; clozapine 350 ng/ml and 420 ng/ml) and incubated with plasma for 24 hours at 37°C. Control samples were performed for each experiment (without the drug). The free thiols level was measured using the Ellman method (acc. to Rice-Evans, 1991). The results were analysed using the paired Student t-test (StatSoft Inc., Statistica v. 6.0). Results: After 24 hours’ incubation with plasma, haloperidol in concentrations 4 ng/ml and20 ng/ml and clozapine in concentrations 350 ng/ml and 420 ng/ml caused statistically insignificant, as compared to control samples (without the drug), modifications in the level of free thiols (p>0.05). Conclusions: Clozapine and haloperidol in concentrations corresponding to doses recommended for treatment of acute episode of schizophrenia, do not induce significant changes in the concentration of free thiols in plasma.
PL
Analizowano zróżnicowane działanie leków przeciwpsychotycznych: haloperidolu i klozapiny na biomarkery stresu oksydacyjnego. Dotychczas nie rozstrzygnięto, w jaki sposób klozapina i haloperidol oddziałują na grupy tiolowe (-SH) osocza ludzkiego. Celem badania było ustalenie wpływu haloperidolu i klozapiny w dawkach rekomendowanych do leczenia ostrego epizodu schizofrenii na wolne tiole w ludzkim osoczu w modelu in vitro. Materiał i metody: Krew do badań pobrano od 10 zdrowych ochotników płci męskiej (w wieku 24-26 lat) na roztwór ACD. Substancję aktywną leków rozpuszczono w 0,01% dimetylosulfotlenku do stężeń końcowych (haloperidol 4 ng/ml i 20 ng/ml; klozapina 350 ng/ml i 420 ng/ml) i inkubowano z osoczem 24 godziny w temperaturze 37°C. Do każdego doświadczenia wykonano próby kontrolne (bez leku). Oznaczenia poziomu wolnych tioli wykonano metodą Ellmana (Rice-Evans, 1991). Do analizy wyników zastosowano sparowany test t-Studenta (StatSoft Inc., Statistica v. 6.0). Wyniki: Ustalono, że po 24-godzinnej inkubacji z osoczem haloperidol w stężeniu 4 ng/ml i 20 ng/ml oraz klozapina w stężeniu 350 ng/ml i 420 ng/ml spowodowały nieistotne statystycznie, w porównaniu z próbami kontrolnymi (bez leku), zmiany poziomu wolnych tioli (p>0,05). Wniosek: Klozapina i haloperidol w stężeniach odpowiadających dawkom rekomendowanym do leczenia ostrego epizodu schizofrenii nie powodują istotnych zmian stężenia wolnych tioli w osoczu.
Discipline
Publisher

Year
Volume
12
Issue
4
Pages
255-264
Physical description
Contributors
  • Pracownia Badań Biologicznych w Psychiatrii, I Katedra Psychiatrii, Uniwersytet Medyczny w Łodzi, Klinika Zaburzeń Afektywnych i Psychotycznych, Uniwersytet Medyczny w Łodzi, tzn_lodz@post.pl
  • Pracownia Badań Biologicznych w Psychiatrii, I Katedra Psychiatrii, Uniwersytet Medyczny w Łodzi
author
  • Pracownia Badań Biologicznych w Psychiatrii, I Katedra Psychiatrii, Uniwersytet Medyczny w Łodzi
References
  • 1. Dietrich-Muszalska A., Olas B., Głowacki R., Bald E.: Oxidative/ nitrative modifications of plasma proteins and thiols from patients with schizophrenia. Neuropsychobiology 2009; 59: 1-7.
  • 2. Dietrich-Muszalska A., Olas B.: Modifications of blood platelet proteins of patients with schizophrenia. Platelets 2009; 20: 90-96.
  • 3. Dietrich-Muszalska A., Olas B.: Isoprostanes as indicators of oxidative stress in schizophrenia. World J. Biol. Psychiatry 2009; 10: 27-33.
  • 4. Khan M.M., Evans D.R., Gunna V. i wsp.: Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr. Res. 2002; 58: 1-10.
  • 5. Dietrich-Muszalska A., Olas B., Rabe-Jablonska J.: Oxidative stress in blood platelets from schizophrenic patients. Platelets 2005; 16: 386-391.
  • 6. Mahadik S.P., Mukherjee S., Correnti E.E., Scheffer R.: Elevated levels of lipid peroxidation products in plasma of drug-naive patients at the onset of psychosis. Schizophr. Res. 1995; 15: 66.
  • 7. Arvindakshan M., Sitasawad S., Debsikdar V. i wsp.: Essential polyunsaturated fatty acid and lipid peroxide levels in nevermedicated and medicated schizophrenia patients. Biol. Psychiatry 2003; 53: 56-64.
  • 8. Jeding I., Evans P.J., Akanmu D. i wsp.: Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs. Biochem. Pharmacol. 1995; 49: 359-365.
  • 9. Lohr J.B., Kuczenski R., Bracha H.S. i wsp.: Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol. Psychiatry 1990; 28: 535-539.
  • 10. Dietrich-Muszalska A., Olas B.: Inhibitory effects of polyphenol compounds on lipid peroxidation caused by antipsychotics (haloperidol and amisulpride) in human plasma in vitro. World J. Biol. Psychiatry 2010; 11: 276-281.
  • 11. Dietrich-Muszalska A., Kontek B., Rabe-Jabłońska J.: Quetiapine, olanzapine and haloperidol affect human plasma lipid peroxidation in vitro. Neuropsychobiology 2011; 63: 197-201.
  • 12. Cadet J.L., Lohr J.B., Jeste D.V.: Free radicals and tardive dyskinesia. Trends Neurosci. 1986; 9: 107-108.
  • 13. Pai B.N., Janakiramaiah N., Gangadhar B.N., Ravindranath V.: Depletion of glutathione and enhanced lipid peroxidation in the CSF of acute psychotics following haloperidol administration. Biol. Psychiatry 1994; 36: 489-491.
  • 14. Sagara Y.: Induction of reactive oxygen species in neurons by haloperidol. J. Neurochem. 1998; 71: 1002-1012.
  • 15. Shivakumar B.R., Ravindranath V.: Oxidative stress and thiol modification induced by chronic administration of haloperidol. J. Pharmacol. Exp. Ther. 1993; 265: 1137-1141.
  • 16. Bai O., Wei Z., Lu W. i wsp.: Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal. J. Neurosci. Res. 2002; 69: 278-283.
  • 17. Dietrich-Muszalska A.: Wpływ różnych stężeń klozapiny na zmiany poziomu peroksydacji lipidów ludzkiego osocza w badaniach in vitro. Psychiatr. Psychol. Klin. 2005; 5: 18-25.
  • 18. Dietrich-Muszalska A.: The impact of haloperidol on lipids peroxidation in human blood platelets and plasma at in vitro studies. Psychiatr. Psychol. Klin. 2004; 4: 150-156.
  • 19. Karatas F., Karatepe M., Baysar A.: Determination of free malondialdehyde in human serum by high-performance liquid chromatography. Anal. Biochem. 2002; 311: 76-79.
  • 20. Bartosz G.: Druga twarz tlenu. Wolne rodniki w przyrodzie. PWN, Warszawa 2009.
  • 21. Włodek L., Iciek M.: S-tiolacja białek jako mechanizm antyoksydacyjny i regulacyjny. Postępy Biochem. 2003; 49: 77-84.
  • 22. Włodek L. (red.): Biotiole w warunkach fizjologicznych, patologicznych i w terapii. Wydawnictwo Uniwersytetu Jagiellońskiego, Kraków 2003.
  • 23. Sheehan D.V., Lecrubier Y., Sheehan K.H. i wsp.: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998; 59 supl. 20: 22-33.
  • 24. Ellman G., Lysko H.: A precise method for the determination of whole blood and plasma sulfhydryl groups. Anal. Biochem. 1979; 93: 98-102.
  • 25. Rice-Evans C.A., Diplock A.T., Symons M.C.R.: Techniques in Free Radical Research. Vol. 22 serii: Burdon R.H., van Knippenberg P.H. (red.): Laboratory Techniques in Biochemistry and Molecular Biology. Elsevier, Amsterdam 1991: 51-100.
  • 26. Bradford M.: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein- dye binding. Anal. Biochem. 1976; 72: 248-254.
  • 27. Mackay A.V.P., Iversen L.L., Rossor M. i wsp.: Increased brain dopamine and dopamine receptors in schizophrenia. Arch. Gen. Psychiatry 1982; 39: 991-997.
  • 28. Mahadik S.P., Mukherjee S.: Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr. Res. 1996; 19: 1-17.
  • 29. Pillai A., Parikh V., Terry A.V. Jr, Mahadik S.P.: Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J. Psychiatr. Res. 2007; 41: 372-386.
  • 30. Parikh V., Khan M.M., Mahadik S.P.: Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J. Psychiatr. Res. 2003; 37: 43-51.
  • 31. Zhang X.Y., Zhou D.F., Cao L.Y. i wsp.: The effect of risperidone treatment on superoxide dismutase in schizophrenia. J. Clin. Psychopharmacol. 2003; 23: 128-131.
  • 32. Zhang X.Y., Zhou D.F., Cao L.Y. i wsp.: Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms. Psychiatry Res. 2003; 117: 85-88.
  • 33. Huang T.L., Liou C.W., Lin T.K.: Serum thiobarbituric acidreactive substances and free thiol levels in schizophrenia patients: effects of antipsychotic drugs. Psychiatry Res. 2010; 177: 18-21.
  • 34. Lohr J.B., Lohr M.A., Wasli E. i wsp.: Self-perception of tardive dyskinesia and neuroleptic-induced parkinsonism: a study of clinical correlates. Psychopharmacol. Bull. 1987; 23: 211-214.
  • 35. Zhang X.Y., Tan Y.L., Cao L.Y. i wsp.: Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr. Res. 2006; 81: 291-300.
  • 36. Dietrich-Muszalska A., Kontek B.: Lipid peroxidation in patients with schizophrenia. Psychiatry Clin. Neurosci. 2010; 64: 469-475.
  • 37. Schatzberg A.F., Nemeroff C.B. (red.): The American Psychiatric Publishing Textbook of Psychopharmacology. Wyd. 3, American Psychiatric Publishing, Inc., Arlington 2004.
  • 38. Reinke A., Martins M.R., Lima M.S. i wsp.: Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain. Neurosci. Lett. 2004; 372: 157-160.
  • 39. Dalla Libera A., Rigobello M.P., Bindoli A.: Inhibitory action of neuroleptic drugs and serotonin on dopamine autoxidation and lipid peroxidation. Prog. Neuropsychopharmacol. Biol. Psychiatry 1995; 19: 291-298.
  • 40. Krzaścik P., Kostowski W.: Nitric oxide donors antagonize N-nitro-L-arginine and haloperidol catalepsy: potential implication for the treatment of parkinsonism? Pol. J. Pharmacol. 1997; 49: 263-266.
  • 41. Chiueh C.C., Rauhala P.: The redox pathway of S-nitrosoglutathione, glutathione and nitric oxide in cell to neuron communications. Free Radic. Res. 1999; 31: 641-650.
  • 42. Do K.Q., Trabesinger A.H., Kirsten-Krüger M. i wsp.: Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur. J. Neurosci. 2000; 12: 3721-3728.
  • 43. Dodd S., Dean O., Copolov D.L. i wsp.: N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin. Biol. Ther. 2008; 8: 1955-1962.
  • 44. Yao J.K., Leonard S., Reddy R.D.: Increased nitric oxide radicals in postmortem brain from patients with schizophrenia. Schizophr. Bull. 2004; 30: 923-934.
  • 45. Taylor D., Paton C., Kerwin R.: The Maudsley 2003 Prescribing Guidelines. Wyd. 7, Martin Dunitz, Taylor & Francis Group, London, New York 2003.
  • 46. Dietrich-Muszalska A., Rabe-Jabłońska J.: Porównanie wpływu działania leków przeciwpsychotycznych – I generacji (haloperidolu) i II generacji (klozapiny, olanzapiny i risperidonu) – na peroksydację lipidów osocza in vitro. Psychiatr. Psychol. Klin. 2007; 7: 210-218.
  • 47. Kropp S., Kern V., Lange K. i wsp.: Oxidative stress during treatment with first- and second-generation antipsychotics. J. Neuropsychiatry Clin. Neurosci. 2005; 17: 227-231.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-307f2975-d253-4ad9-8313-19356204fb3d
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.